Clozapine--should race affect prescribing guidelines?
Mallinger
Julie B
JB
Lamberti
J Steven
JS
D000380:Agranulocytosis / Q000139:chemically induced / Q000517:prevention & control; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D044383:Black People; D002170:Canada; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring; D004363:Drug Utilization / Q000592:standards*; D006801:Humans; D017410:Practice Guidelines as Topic; D012559:Schizophrenia / Q000188:drug therapy* / Q000208:ethnology; D006113:United Kingdom; D014481:United States; D001741:Black or African American
D014150:Antipsychotic Agents; D003024:Clozapine